79 related articles for article (PubMed ID: 19141584)
1. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
de Bruin C; Pereira AM; Feelders RA; Romijn JA; Roelfsema F; Sprij-Mooij DM; van Aken MO; van der Lelij AJ; de Herder WW; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2009 Apr; 94(4):1118-24. PubMed ID: 19141584
[TBL] [Abstract][Full Text] [Related]
2. Current and Emerging Pharmacological Therapies for Cushing's Disease.
Divaris E; Kostopoulos G; Efstathiadou ZA
Curr Pharm Des; 2024; 30(10):757-777. PubMed ID: 38424426
[TBL] [Abstract][Full Text] [Related]
3. Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
Serioli S; Agostini L; Pietrantoni A; Valeri F; Costanza F; Chiloiro S; Buffoli B; Piazza A; Poliani PL; Peris-Celda M; Iavarone F; Gaudino S; Gessi M; Schinzari G; Mattogno PP; Giampietro A; De Marinis L; Pontecorvi A; Fontanella MM; Lauretti L; Rindi G; Olivi A; Bianchi A; Doglietto F
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958702
[TBL] [Abstract][Full Text] [Related]
4. The dopaminergic control of Cushing's syndrome.
Pivonello R; Pivonello C; Simeoli C; De Martino MC; Colao A
J Endocrinol Invest; 2022 Jul; 45(7):1297-1315. PubMed ID: 35460460
[TBL] [Abstract][Full Text] [Related]
5. Current and Emerging Medical Therapies in Pituitary Tumors.
Sahakian N; Castinetti F; Brue T; Cuny T
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207228
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
7. Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease.
Machado MC; Cescato VAS; Fragoso MCBV; Bronstein MD
AACE Clin Case Rep; 2021; 7(4):277-281. PubMed ID: 34307853
[TBL] [Abstract][Full Text] [Related]
8. Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Terreni M; Lasio G; Losa M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183012
[TBL] [Abstract][Full Text] [Related]
9. Treatment challenges in pediatric Cushing's disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence.
Pasternak-Pietrzak K; Moszczyńska E; Szalecki M
Endocrine; 2019 Nov; 66(2):125-136. PubMed ID: 31701434
[TBL] [Abstract][Full Text] [Related]
10. Co-expression Network Analysis Elucidated a Core Module in Association With Prognosis of Non-functioning Non-invasive Human Pituitary Adenoma.
Aydin B; Arga KY
Front Endocrinol (Lausanne); 2019; 10():361. PubMed ID: 31244774
[TBL] [Abstract][Full Text] [Related]
11. The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor.
Wang X; Wang ZB; Luo C; Mao XY; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
J Cancer; 2019; 10(7):1622-1632. PubMed ID: 31205518
[TBL] [Abstract][Full Text] [Related]
12. Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.
Herrera-Martínez AD; Feelders RA; de Herder WW; Castaño JP; Gálvez Moreno MÁ; Dogan F; van Dungen R; van Koetsveld P; Hofland LJ
Horm Cancer; 2019 Jun; 10(2-3):107-119. PubMed ID: 31102172
[TBL] [Abstract][Full Text] [Related]
13. High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma.
Behling F; Honegger J; Skardelly M; Gepfner-Tuma I; Tabatabai G; Tatagiba M; Schittenhelm J
Int J Endocrinol; 2018; 2018():1763735. PubMed ID: 30627156
[TBL] [Abstract][Full Text] [Related]
14. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.
Günther T; Tulipano G; Dournaud P; Bousquet C; Csaba Z; Kreienkamp HJ; Lupp A; Korbonits M; Castaño JP; Wester HJ; Culler M; Melmed S; Schulz S
Pharmacol Rev; 2018 Oct; 70(4):763-835. PubMed ID: 30232095
[TBL] [Abstract][Full Text] [Related]
15. Dopamine Agonists for Pituitary Adenomas.
Cooper O; Greenman Y
Front Endocrinol (Lausanne); 2018; 9():469. PubMed ID: 30186234
[TBL] [Abstract][Full Text] [Related]
16. Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.
Palui R; Sahoo J; Kamalanathan S; Kar SS; Selvarajan S; Durgia H
J Endocrinol Invest; 2018 Dec; 41(12):1445-1455. PubMed ID: 30097903
[TBL] [Abstract][Full Text] [Related]
17. Update on medical treatment for Cushing's disease.
Cuevas-Ramos D; Lim DST; Fleseriu M
Clin Diabetes Endocrinol; 2016; 2():16. PubMed ID: 28702250
[TBL] [Abstract][Full Text] [Related]
18. Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy.
Uraki S; Ariyasu H; Doi A; Furuta H; Nishi M; Usui T; Yamaue H; Akamizu T
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28458907
[TBL] [Abstract][Full Text] [Related]
19. Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms.
Mooney MA; Simon ED; Little AS
Front Surg; 2016; 3():45. PubMed ID: 27517036
[TBL] [Abstract][Full Text] [Related]
20. A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.
Malek M; Esfehanian F; Amouzegar A; Sarvghadi F; Moossavi Z; Mohajeri-Tehrani MR; Khamseh ME; Amirbaigloo A; Ebrahim Valojerdi A
Med J Islam Repub Iran; 2016; 30():334. PubMed ID: 27390704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
